** Shares in Sartorius SATG.DE soar around 9% to
three-week high after the Franco-German lab supplies maker said
it expects its sales revenue and margin to rise in 2024, and
announced new mid-term targets
** For 2024, the company forecasts an increase in group
sales revenue in the mid-to-high single-digit percentage range,
and projects average double-digit annual growth through to 2028
** It expects underlying EBITDA margin to rise to slightly
more than 30% in 2024, from 28.3% last year
** "While the FY 24 sales guidance seems in line with market
expectations, the margin guidance suggests some upside to
estimates," says Michael Heider from Warburg Research
** Heider adds that the new mid-term outlook suggests a
return to historic growth rates, which is certainly "positive"
** "While the FY 23 numbers are largely in-line and mid-term
outlook implies a low-to-mid single digit cut to consensus, the
stock is likely rising on account of a relief rally," says
Virendra Chauhan from AlphaValue
** If gains hold, the stock will see its best day in nearly
three years
** Its French unit Sartorius Stedim Biotech STDM.PA
jumps 6%
(Reporting by Mateusz Dobrzyniewski)
((Mateusz.dobrzyniewski@thomsonreuters.com))